Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Here’s Why

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $27.37, but opened at $25.6501. Chugai Pharmaceutical shares last traded at $26.68, with a volume of 325,235 shares trading hands.

Chugai Pharmaceutical Trading Down 2.5%

The company has a market capitalization of $87.84 billion, a price-to-earnings ratio of 33.36 and a beta of 0.63. The firm’s 50 day simple moving average is $24.89 and its 200-day simple moving average is $24.09.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its earnings results on Friday, October 24th. The company reported $0.23 EPS for the quarter. The company had revenue of $2.26 billion during the quarter. Chugai Pharmaceutical had a return on equity of 20.63% and a net margin of 32.74%. As a group, sell-side analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.